Clinical Trials Directory

Trials / Completed

CompletedNCT03047057

Lidocaine Infusion in Radical Cystectomy

Effect of Lidocaine Infusion on Acute Rehabilitation After Radical Cystectomy

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
57 (actual)
Sponsor
Assiut University · Academic / Other
Sex
All
Age
45 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Radical cystectomy (RC) remains the gold standard for treatment of patients with muscle invasive bladder cancer, or recurrent high grade non-muscle invasive bladder cancer. Nowadays, enhanced recovery pathway is used to decrease morbidity and improve acute rehabilitation after RC. Postoperative ileus is the most frequent reason for prolonged hospital stay following cystectomy.

Detailed description

Radical cystectomy remains the gold standard for treatment of patients with muscle invasive bladder cancer, or recurrent high grade non-muscle invasive bladder cancer. The high rates of morbidity and mortality reflect the fact that the majority of patients undergoing this procedure are elderly patients with multiple comorbidities. Postoperative ileus is the most frequent reason for prolonged hospital stay following cystectomy. To reduce the risk of ileus, prokinetics such as metoclopramide should be used postoperatively. Local anesthetics exert their actions as local anesthesia and antiarrhythmic through Na channels blocking but still have many other important actions through other receptors (e.g., m1 muscarinic receptors) that occur at very low plasma levels compared to levels needed for Na channels blocking, one of these actions is the anti-inflammatory effect against surgical stress response. Several randomized studies found that i.v. lidocaine shortens duration of postoperative ileus and some of it reported decreased postoperative pain with i.v. lidocaine, so they recommended i.v. lidocaine as a safe, simple, and less invasive method for management of postoperative ileus and equal to postoperative epidural analgesia.

Conditions

Interventions

TypeNameDescription
DRUGLidocaineIV Lidocaine infusion
DRUGIV normal salineIV normal saline infusion

Timeline

Start date
2017-03-03
Primary completion
2018-07-20
Completion
2018-07-20
First posted
2017-02-08
Last updated
2018-08-07

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT03047057. Inclusion in this directory is not an endorsement.